Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089517 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
A Phase 2 study, sponsored by Ophthotech Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 449
- Enrollment target
NCT01089517: Completed Phase 2 study, sponsored by Ophthotech Corporation.
NCT01089517 is a Phase 2 study that has completed, run by Ophthotech Corporation. The registered enrollment target is 449 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01089517, a Phase 2 study, has completed, sponsored by Ophthotech Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 449 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Interventions
- DRUG Lucentis
- DRUG E10030 plus Lucentis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089517
The ClinicalTrials.gov registry entry for NCT01089517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lucentis is the first listed.
NCT01089517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089517 about?
NCT01089517 is a clinical study titled "A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration". The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT01089517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 449 participants. The study started on 2010-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01089517?
The interventions under investigation include: Lucentis (DRUG), E10030 plus Lucentis (DRUG).
Who is sponsoring clinical trial NCT01089517?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.